H. Lundbeck A — Director's Dealing 2009

Mar 9, 2009

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

Announcement of transactions with shares and linked securities in H. Lundbeck A/S made by executives and their closely associated persons and legal entities

H. Lundbeck A/S hereby reports transactions made by executives and persons and legal entities closely associated to them with shares in H. Lundbeck A/S and linked securities, cf. section 28a of the Danish Securities Trading Act.

The list is based on reports received by H. Lundbeck A/S from the company's executives today or yesterday.

Name:	Per Wold-Olsen
Job position of the executive:	Chairman of Supervisory Board
Relation to executive (associated person or legal entity):
ID code (ISIN code):	DK 0010287234 / CUSIP 40422M107
Description of the security:	ADR
Nature of the transaction:	Purchase of ADR
Date of trading:	6 March 2009
Market on which the trading was effected:	Pink Sheets Level 1 / unsponsored program
Number of traded securities:	10,000	ADR
Market price of securities traded:	1,021,300.00	DKK

Persons/entities under an obligation to report

Persons or entities under an obligation to report are defined as members of the Executive Management and the Supervisory Board of H. Lundbeck A/S and persons/entities closely associated to them.

Closely associated persons/entities means inter alia:

• spouse or cohabitant

• children below the age of 18

• legal entities in which the insider has a controlling influence

The content of this release will have no influence on the Lundbeck Group's financial result for 2009.

Lundbeck contacts

Investors:	Media:
Jacob Tolstrup	Mads Kronborg
Director, IR & Communication	Media Relations
+45 36 43 30 79	+45 36 43 28 51
Palle Holm Olesen
Head of Investor Relations
+45 36 43 24 26

About Lundbeck

H. Lundbeck A/S (LUN.CO, LUN DC, HLUKY) is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2008, the company's revenue was DKK 11.3 billion (approximately EUR 1.5 billion or USD 2.2 billion). The number of employees is approx. 5,500 globally. For more information, please visit www.lundbeck.com. 

Attachments:

• Release no 367

  ---

  This content was distributed through

  

  - connecting communication professionals with their target audience. Visit us here.